AMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
AMARIN CORP PLC\UK
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$11.53+0.21 (+1.86%)
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$8.11 (−41.29%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
AMARIN CORP PLC\UK saw revenue fall 15.1% to $186.23M over the twelve months to Jun 30, 2026.
Revenue
$186.23M
-15.1% vs. a year earlier
Operating income
-$40.77M
TTM Q2 2026
EPS, diluted
-$0.07
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.80B
- P/E ratio
- –
- Price to sales
- 25.78
- Price to book
- 10.82
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $186.23M
- Net income
- -$27.12M
- EPS, diluted
- -$0.07
- Book value per share
- $1.07
- Diluted shares
- 416M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$186.23M-15.1% YoY
Gross profit
$78.14M-4.9% YoY
Operating income
-$40.77M
Net income
-$27.12M
EPS, diluted
-$0.07
Free cash flow
–
Reported periodTrailing twelve months